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explanation for these phenomena may be the presence of profound endothelial dysfunction and injury.
This review provides an overview on the association of endothelial dysfunction with COVID-19 and its
therapeutic implications. Endothelial dysfunction is a common feature of the key comorbidities that in-
crease risk for severe COVID-19 such as hypertension, obesity, diabetes mellitus, coronary artery disease
or heart failure. Preliminary studies indicate that vascular endothelial cells can be infected by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), and evidence of widespread endothelial injury and
inflammation is found in advanced cases of COVID-19. Prior evidence has established the crucial role of
endothelial cells in maintaining and regulating vascular homeostasis and blood coagulation. Aggravation
of endothelial dysfunction in COVID-19 may therefore impair organ perfusion and cause a procoagula-
tory state resulting in both macro- and microvascular thrombotic events. Angiotensin-converting enzyme
(ACE) inhibitors, angiotensin receptor blockers (ARBs) and statins are known to improve endothelial
dysfunction. Data from smaller observational studies and other viral infections suggests a possible ben-
eficial effect in COVID-19. Other treatments that are currently under investigation for COVID-19 may
also act by improving endothelial dysfunction in patients. Focusing therapies on preventing and improv-
ing endothelial dysfunction could improve outcomes in COVID-19. Several clinical trials are currently
underway to explore this concept.
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Coronavirus disease 2019 (COVID-19) increases the risk of several non-pulmonary complications such as acute 
myocardial injury, renal failure or thromboembolic events. A possible unifying explanation for these phenomena 
may be the presence of profound endothelial dysfunction and injury. This review provides an overview on the 
association of endothelial dysfunction with COVID-19 and its therapeutic implications. Endothelial dysfunction is 
a common feature of the key comorbidities that increase risk for severe COVID-19 such as hypertension, obesity, 
diabetes mellitus, coronary artery disease or heart failure. Preliminary studies indicate that vascular endothelial 
cells can be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and evidence of 
widespread endothelial injury and inflammation is found in advanced cases of COVID-19. Prior evidence has 
established the crucial role of endothelial cells in maintaining and regulating vascular homeostasis and blood 
coagulation. Aggravation of endothelial dysfunction in COVID-19 may therefore impair organ perfusion and 
cause a procoagulatory state resulting in both macro- and microvascular thrombotic events. Angiotensin- 
converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and statins are known to improve 
endothelial dysfunction. Data from smaller observational studies and other viral infections suggests a possible 
beneficial effect in COVID-19. Other treatments that are currently under investigation for COVID-19 may also act 
by improving endothelial dysfunction in patients. Focusing therapies on preventing and improving endothelial 
dysfunction could improve outcomes in COVID-19. Several clinical trials are currently underway to explore this 
concept.   
1. Introduction 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic is significantly affecting socioeconomic and healthcare sys-
tems worldwide. The pathophysiology of its associated disease, coro-
navirus disease 2019 (COVID-19), is still largely unclear and under 
active investigation. This article provides an overview on recent evi-
dence linking endothelial dysfunction with COVID-19 and its potential 
implications for preventing adverse outcomes and treating the disease. 
1.1. Endothelial dysfunction: a common denominator in patients at risk 
for COVID-19 
Preliminary studies indicate that patients with cardiovascular risk 
factors and/or established cardiovascular disease have the highest risk 
of being hospitalized with COVID-19 and developing a more severe 
disease course. These risk factors include older age (>65 years), 
hypertension, obesity, diabetes mellitus, chronic lung disease, coronary 
artery disease and heart failure [1–4]. 
Interestingly, a common denominator of all these cardiometabolic 
diseases is endothelial dysfunction. The endothelium is crucial for 
maintaining vascular tone and homeostasis – dysfunction is associated 
with vasoconstriction, inflammation, permeability, and coagulation. It is 
associated with major risk factors such as age, hypertension, diabetes 
mellitus, and obesity, as well as development and progression of car-
diovascular diseases [5]. Classically, endothelial function is assessed by 
measuring the dilatation of brachial or coronary arteries in response to 
shear stress or external stimuli [6]. Newer methods also allow the 
assessment of smaller vascular beds such as the retinal microcirculation 
[7]. 
1.2. SARS-CoV-2 target endothelial cells 
The primary site of infection in COVID-19 is the upper and lower 
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respiratory tract. There, SARS-CoV-2 infects goblet secretory cells of the 
nasal mucosa and alveolar type II pneumocytes by binding to 
membrane-bound angiotensin-converting enzyme 2 (ACE2) [8]. After 
priming of the virus spike protein and cleavage of ACE2 by the human 
protease TMPRSS2, the virus is internalized into the cell and viral 
replication begins. In severe COVID-19, there is a progressive infection 
of alveolar pneumocytes with significant viral shedding resulting in 
apoptosis and necrosis [9]. Interferon-mediated upregulation of ACE2 
may facilitate infection of adjacent pneumocytes [8]. The subsequent 
immune reaction leads to progressive interstitial and alveolar edema, 
which impairs gas exchange and may eventually result in acute respi-
ratory distress syndrome (ARDS). 
Already shortly after the outbreak, reports suggested that COVID-19 
affects other organs beyond the lung, most importantly the heart and 
kidney [10,11]. In severe COVID-19, evidence of acute myocardial 
injury (elevation of cardiac troponins) is common, and is associated with 
impaired prognosis. In light of the tissue tropism of SARS-CoV-2 for 
ACE2-expressing cells, another major organ of the body is an important 
target of infection: the vascular endothelium [57]. Indeed, ACE2 is 
expressed abundantly on vascular endothelial cells of both small and 
large arteries and veins [56]. We recently demonstrated viral inclusion 
structures within endothelial cells of glomerular capillary loops and 
signs of widespread endotheliitis in the heart, lung, kidney, liver and 
gastrointestinal tract in pathological specimens from 3 patients with 
severe COVID-19 [12]. Endothelial injury and dysfunction may be the 
result of direct infection by SARS-CoV-2 (e.g. by inducing intracellular 
oxidative stress [13]) as well as due to the profound systemic inflam-
matory response. In light of the potential association of COVID-19 with 
endothelial injury, it seems plausible that patients with preexisting 
endothelial dysfunction are vulnerable to a more severe disease course 
given the crucial role of endothelial cells for vascular homeostasis and 
organ perfusion. 
1.3. COVID-19-associated endotheliitis triggers organ damage and 
thrombotic events 
Systemic endotheliitis can explain end-organ damage in severe 
COVID-19. In a case series from New York [14], one third of COVID-19 
patients with electrocardiographic signs of active ischemia showed 
non-obstructive coronary artery disease, and thus microvascular 
dysfunction as a likely cause of ischemia. Myocardial inflammation as 
evidenced by increased cardiac troponins or magnet resonance imaging 
abnormalities is not uncommon in severe COVID-19 [15,16]. 
SARS-CoV-2 has been isolated from cardiac autopsy samples, however, 
this was not regularly associated with an infiltration of immune cells as 
seen in myocarditis [17]. The virus may rather affect the endothelium 
leading to secondary myocardial inflammation and dysfunction. The 
phenotype of myocardial dysfunction and ischemic electrocardiographic 
features in the absence of coronary obstruction or myocarditis is remi-
niscent of Takotsubo syndrome, which is also associated with endothe-
lial dysfunction [18]. 
Vascular endothelial cells play a critical role in vascular homeostasis 
and the coagulation system. While healthy endothelial cells naturally 
express factors that induce vascular relaxation and increase blood flow, 
inhibit platelet aggregation and coagulation, and promote fibrinolysis, 
dysfunctional endothelial cells shift the balance towards vascular 
contraction and thrombus formation [19]. Most cardiovascular risk 
factors indeed cause a decreased endothelial production of vasorelaxing 
and antithrombotic mediators and a concomitantly increased formation 
of contracting and prothrombotic factors [20]. In severe COVID-19, 
markers of both endothelial and platelet activation are increased 
compared to controls [21]. Extensive microthrombosis promoted and 
aggravated by endothelial dysfunction could explain the profound 
elevation of D-dimers and thrombocytopenia in severe COVID-19 [3]. In 
line with these haematologic findings, recent reports show increased risk 
of both venous and arterial thrombotic events in COVID-19 [22,23]. A 
recent case series also suggested that pulmonary microthrombi and 
pulmonary endothelial dysfunction explain the unusual dead-space and 
shunt physiology found in severe COVID-19 patients [24]. Indeed, sig-
nificant pulmonary endotheliitis, microvascular thrombosis and evi-
dence of pulmonary endothelial infection by SARS-CoV2 was observed 
in another pathological case series [25]. Pulmonary microvascular 
dysfunction may therefore be an underlying mechanism behind the 
phenomenon of severe hypoxia despite relatively preserved lung me-
chanics in COVID-19 [26]. In children with COVID-19-associated chil-
blains of the extremities, profound endothelial inflammation along with 
endothelial infection with SARS-CoV2 was observed in a small case se-
ries [27]. 
1.4. Targeting endothelial dysfunction in COVID-19 
Most therapies under active investigation for COVID-19 focus on 
inhibition of viral replication and suppression of the excessive immune 
response. However, in light of the above, treatment of endothelial 
dysfunction is a promising approach to protect vulnerable patients and 
to improve outcomes in COVID-19. Many studies have demonstrated the 
possibility to enhance vascular function via lifestyle interventions and 
drug therapies [28]. Two widely used drug classes, renin angiotensin 
system (RAS) inhibitors and statins, have been shown in an abundant 
number of studies to consistently improve endothelial function in pa-
tients. Both drug classes exert pleiotropic effects on the endothelium and 
promote endothelium-induced stimulation of vascular relaxation as well 
as endothelium-mediated inhibition of thrombus formation. 
1.4.1. RAS inhibitors 
Angiotensin II is a well-known mediator of endothelial dysfunction, 
which is in part mediated by increased oxidative stress following 
angiotensin II receptor type 1 activation [29]. Indeed, both ACE in-
hibitors and angiotensin receptor blockers (ARBs) have been shown to 
improve endothelial dysfunction [30,31]. They may also attenuate 
procoagulatory states by reducing the expression of tissue factor in 
endothelial cells and other cell types [32]. The use of RAS inhibitors is 
not without controversy in COVID-19: They are associated with an 
upregulation of ACE2, which may (theoretically) increase susceptibility 
to infection. However, ACE2 is a part of the natural host response against 
pulmonary infections [33] and antagonizes RAS activation by hydrolysis 
of angiotensin II into angiotensin (1–7), a vasodilator with anti-oxidant 
and anti-inflammatory effects [34]. ACE2 is downregulated after inva-
sion of SARS-CoV-2 into cells. This may lead to unopposed RAS activa-
tion resulting in endothelial injury and a pro-inflammatory and 
pro-thrombotic state in COVID-19 – which may be amendable by 
pharmacological RAS blockade [35]. Indeed, the use of RAS inhibitors 
was not associated with a higher risk of SARS-CoV-2 infection or an 
adverse outcome in recent observational studies [36–39]. In a Spanish 
population-based study, a borderline-significant reduced risk for 
COVID-19 hospital admissions was found with ACE inhibitors and a 
lower risk for patients with diabetes who were treated with RAS in-
hibitors vs. non-users [40]. A trend of lower COVID-19-related mortality 
with RAS inhibitors was also found in a meta-analysis of four studies 
[41]. In a UK cohort study, RAS inhibitors were associated with a lower 
risk of COVID-19 [42]. Recently, results from the first randomized trial 
on this topic were presented (BRACE-CORONA) [43]. In this trial, 
discontinuation of RAS inhibitors in hospitalized patients with 
COVID-19 had no beneficial effect compared to continuation of therapy. 
Therefore, it is recommended to continue RAS inhibitors in COVID-19 
patients who are already on such therapies as long as there are no 
acute contraindications such as severe kidney injury, significant 
hyperkalemia or symptomatic hypotension. Whether general RAS 
blockade in COVID-19 is beneficial needs to be confirmed in clinical 
trials. Several intervention studies with ACE inhibitors and ARBs 
currently explore this hypothesis (Table 1 and Supplementary Table 1). 
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Table 1 
Selecteda randomized controlled trials (ongoing or planned) on interventions in COVID-19 that are also known to improve endothelial function.  
Trial identifier (Trial acronym) Description of intervention Country Estimated 
enrollment 
NCT04328012 (COVIDMED) Losartan vs placebo (other arms: lopinavir/ritonavir, hydroxychloroquine) in patients with COVID-19 
and not on previous RAS inhibition 
USA 4000 
NCT04330300 (CORONACION) Continuation of RAS inhibitors vs. switch to different antihypertensive drug in patients with COVID-19, 
hypertension and previously on a RAS inhibitor 
Ireland 2414 
NCT04366050 (RAMIC) Ramipril vs. placebo for 14 days in patients with COVID-19 in non-intensive care setting USA 560 





Rosuvastatin vs. no treatment in patients with COVID-19 who required hospitalization Spain 1080 
NCT04333407 (C-19-ACS) Atorvastatin combined with aspirin, clopidogrel, omeprazole and very-low dose rivaroxaban vs. control 
in patients with COVID-19 and elevated cardiovascular risk 
International 3170 
NCT04380402 (STATCO19) Atorvastatin vs. standard-care of atorvastatin as an adjunctive treatment in COVID-19 in non-ICU 
patients not on prior statin therapy 
USA 300 
NCT04401150 (LOVIT-COVID) Intravenous vitamin C vs. placebo in hospitalized COVID-19 patients Canada 800 
NCT04342728 (COVIDAtoZ) Vitamin C, zinc or the combination vs. standard of care in ambulatory COVID-19 patients USA 520 
NCT04335084 (HELPCOVID-19) Vitamin C, hydroxychloroquine, vitamin D and zinc vs. placebo for the prevention of COVID-19 
infection in non-infected patients 
USA 600 
NCT04400890 Plant polyphenol supplement vs. placebo on top of vitamin D in outpatients with mild COVID-19 USA 200 
NCT04404218 (ACAI) Acai palm berry extract for 30 days vs. placebo in patients with mild to moderate COVID-19 Canada 480 
COVID-19, coronavirus disease 2019; NCT, national clinical trial identifier; RAS, renin angiotensin system. 
a For the complete list see Supplementary Table 1. 
Fig.1. Mechanisms of endothelial dysfunction in COVID-19. 
SARS-CoV-2 could aggravate endothelial dysfunction and lead to systemic complications by several mechanisms. (1) The inflammatory reaction in COVID-19 can 
activate the renin angiotensin system (RAS) either directly via increasing angiotensin I (Ang I), or indirectly by reducing the surface expression of angiotensin- 
converting enzyme 2 (ACE2). ACE2 is responsible for the hydrolysis of Ang II into the vasodilator Ang (1-7), which opposes the actions of Ang II thereby coun-
terbalancing RAS activation. (2) Activation of the angiotensin II type 1 receptor (AT1R), along with direct infection of endothelial cells by the virus, (3) increases 
reactive oxygen species (ROS) and activates nuclear factor kappa B (NF-kB), which inactivates nitric oxide (NO) to peroxynitrite and reduces its production by 
uncoupling endothelial NO synthase (eNOS). (4) Activation of several cytokine receptors (e.g. tumor necrosis factor alpha receptor, interleukin 6 receptor) can 
directly or indirectly impair endothelial function. Endothelial dysfunction in turn impairs organ perfusion by disrupting the balance between vasoconstriction and 
dilatation, increases inflammation and leads to a pro-thrombotic state in both larger and smaller vessels, such as by increasing tissue factor and favoring platelet 
activation. This vicious cycle may be amendable by treatments targeting different steps of the cascade, such as ACE inhibitors, angiotensin receptor blockers (ARBs), 
cytokine inhibitors (e.g. interleukin 6 receptor antibodies) or statins. Statins may be helpful by reducing oxidized LDL levels and NADPH oxidase activity, which 
decrease reactive oxygen species (ROS), directly or indirectly affecting the transcription of NF-kB or by improving coupling of eNOS. Measures to prevent and treat 
important comorbidities could also be helpful along with selected supplements such as antioxidants. 
M.P. Nägele et al.                                                                                                                                                                                                                               
Atherosclerosis 314 (2020) 58–62
61
1.4.2. Statins 
Statins are another promising drug class for treating endothelial 
dysfunction and preventing vascular damage in COVID-19. Similar to 
RAS inhibitors, statins improve endothelial function in patients with or 
at risk for cardiovascular disease [44]. They improve endothelial func-
tion via different mechanisms, including reduction of oxidized 
low-densitiy lipoprotein cholesterol, increased expression and improved 
coupling of endothelial nitric oxide synthase (eNOS), suppression of 
pro-oxidant enzymes such as NADPH oxidase and inhibition of nuclear 
factor kappa B (NF-κB) and other pro-inflammatory transcriptional and 
signal transduction pathways [45–47]. Independent of nitric oxide, 
statins prevent tissue factor expression in endothelial cells [48] which 
may favorably affect blood coagulation and platelet activation [46]. We 
previously showed that statins improve endothelial dysfunction in 
rheumatoid arthritis [49], suggesting that they may be particularly 
helpful in inflammatory conditions characterized by endothelial 
dysfunction. Some evidence points toward a beneficial effect in viral 
pneumonias such as influenza [50]. Larger studies on the effects of 
statins in COVID-19 are still pending. A small observational study in 
elderly nursing home subjects suggested a higher chance of a 
symptom-free COVID-19 infection in statin-users vs. non-users [39]. In a 
retrospective cohort study in China, statin use was associated with lower 
mortality compared to non-use in COVID-19 [51]. Several intervention 
studies studying the role of statins in COVID-19 have recently been 
announced (Supplementary Table 1). Until then, it seems prudent to 
continue statins in COVID-19 patients who already received the drugs 
before infection and initiate statins in all patients who meet cardiovas-
cular guideline-criteria supporting their use. 
1.4.3. Anti-inflammatory therapies 
Several anti-inflammatory therapies under investigation for COVID-19 
may partly act by improving endothelial function. For example, 
improvement of endothelial dysfunction has been described for tumor 
necrosis factor alpha inhibitors [52] or anti-IL-6 receptor antibodies [53]. 
1.4.4. Other approaches 
Beyond drug therapies, the importance of effective preventive mea-
sures cannot be overstated during the current pandemic. In that regard, 
improving or maintaining a normal endothelial function by well- 
established lifestyle measures (i.e. keeping a normal weight, regular 
physical activity, abstaining from smoking and consuming a healthy and 
nutritious diet) may be helpful to reduce the risk of COVID-19. Specific 
supplemental interventions that reduce endothelial dysfunction (e.g. 
antioxidants [54], flavanols [55]) could also be considered for further 
testing. Of note, several trials studying the effects of vitamin C, antiox-
idants and polyphenols in COVID-19 have been started (Supplementary 
Table 1). 
2. Conclusions 
Accumulating evidence points toward an important role of endo-
thelial dysfunction in the pathogenesis of COVID-19 (Fig. 1). Therapies 
aiming to improve endothelial dysfunction such as RAS inhibitors or 
statins may be particularly helpful to prevent and manage systemic 
complications of SARS-CoV-2 infection. Based on the current evidence, 
we recommend to continue RAS inhibitors and statins in patients with 
COVID-19 as long as there are no acute contraindications. For preven-
tion, we recommend that patients with a cardiovascular indication as 
per current guidelines should be prescribed RAS inhibitors and statins 
along with optimal lifestyle measures. Whether these therapies are 
beneficial in COVID-19 patients without such indications needs to be 
evaluated and tested in upcoming clinical trials. 
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